Provided by Tiger Trade Technology Pte. Ltd.

Contineum Therapeutics, INC.

13.12
+0.13001.00%
Post-market: 13.120.00000.00%19:30 EDT
Volume:794.26K
Turnover:10.35M
Market Cap:493.59M
PE:-7.63
High:13.24
Open:13.15
Low:12.59
Close:12.99
52wk High:17.79
52wk Low:8.60
Shares:37.62M
Float Shares:31.54M
Volume Ratio:0.95
T/O Rate:2.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7201
EPS(LYR):-2.1700
ROE:-28.01%
ROA:-19.15%
PB:2.06
PE(LYR):-6.05

Loading ...

Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint

Dow Jones
·
Sep 15

Contineum Therapeutics Reports Phase 2 MOONLIGHT-1 Results

TIPRANKS
·
Sep 15

Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal

Reuters
·
Sep 15

Contineum says MOONLIGHT-1 trial did not achieve its primary endpoint

TIPRANKS
·
Sep 15

Contineum down 11% atter MOONLIGHT-1 trial did not achieve endpoint

TIPRANKS
·
Sep 15

Contineum Therapeutics, - Jnj-5120/Pipe-307 Well-Tolerated with no New Safety Signals

THOMSON REUTERS
·
Sep 15

Contineum Therapeutics, - Analyses of Data Including Exploratory Endpoints are Ongoing

THOMSON REUTERS
·
Sep 15

Contineum Therapeutics Reports Phase 2 Results for Jnj-5120/Pipe-307 for the Treatment of Major Depressive Disorder

THOMSON REUTERS
·
Sep 15

Contineum Therapeutics, - Phase 2 Moonlight-1 Trial Did not Meet Primary Efficacy Endpoint

THOMSON REUTERS
·
Sep 15

Contineum Therapeutics, - Johnson & Johnson Continues to Evaluate Trial Data for Jnj-5120/Pipe-307

THOMSON REUTERS
·
Sep 15

Contineum Therapeutics CEO Carmine N. Stengone Disposes of 2,500 Common Shares for $41,141.5

Reuters
·
Sep 09

Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from RBC Capital

TIPRANKS
·
Sep 03

Contineum Therapeutics to Present at Morgan Stanley Global Healthcare Conference

Reuters
·
Aug 26

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

MT Newswires Live
·
Aug 17

Contineum Therapeutics, Inc. Class A (CTNM) Gets a Hold from Morgan Stanley

TIPRANKS
·
Aug 17

Morgan Stanley Adjusts PT on Contineum Therapeutics to $18 From $16, Keeps Equalweight Rating

MT Newswires Live
·
Aug 17

Contineum Therapeutics CEO Carmine Stengone Disposes of Shares Worth $40,029

Reuters
·
Aug 04

Contineum Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 03

Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines

TIPRANKS
·
Aug 01

Contineum Therapeutics is Maintained at Outperform by RBC Capital

Dow Jones
·
Aug 01